Alembic Builds US Launch Pipeline As It Looks To Oncology Arena

 
• By Aidan Fry

Alembic is building up an extensive roster of solid-dose, ophthalmic and dermatological drugs to introduce in the US. With facility clearance from the FDA, the Indian firm can now target the US market for oral solids to treat cancer.

Bank notes
Alembic is rapidly adding to its roster of US generics as approvals come through • Source: Shutterstock

More from Manufacturing

More from Business